These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
215 related items for PubMed ID: 7553617
1. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ. Cancer Res; 1995 Oct 15; 55(20):4507-11. PubMed ID: 7553617 [Abstract] [Full Text] [Related]
2. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. J Clin Oncol; 1996 Jan 15; 14(1):249-56. PubMed ID: 8558205 [Abstract] [Full Text] [Related]
3. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Yao K, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ. Cancer Res; 1993 Aug 15; 53(16):3662-6. PubMed ID: 8101766 [Abstract] [Full Text] [Related]
4. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. J Clin Oncol; 1994 Jan 15; 12(1):194-205. PubMed ID: 8270977 [Abstract] [Full Text] [Related]
5. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK. Cancer Res; 1989 Oct 01; 49(19):5385-91. PubMed ID: 2766304 [Abstract] [Full Text] [Related]
6. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice. Soble MJ, Dorr RT. Anticancer Res; 1988 Oct 01; 8(1):17-22. PubMed ID: 3358633 [Abstract] [Full Text] [Related]
7. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Kramer RA, Greene K, Ahmad S, Vistica DT. Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359 [Abstract] [Full Text] [Related]
8. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells. Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E. Mol Pharmacol; 1996 Jun 15; 49(6):1012-20. PubMed ID: 8649339 [Abstract] [Full Text] [Related]
9. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC. Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674 [Abstract] [Full Text] [Related]
11. The role of glutathione in lymphocyte activation. I. Comparison of inhibitory effects of buthionine sulfoximine and 2-cyclohexene-1-one by nuclear size transformation. Hamilos DL, Wedner HJ. J Immunol; 1985 Oct 01; 135(4):2740-7. PubMed ID: 4031498 [Abstract] [Full Text] [Related]
12. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. Chen G, Zeller WJ. Anticancer Res; 1991 Oct 01; 11(6):2231-7. PubMed ID: 1776864 [Abstract] [Full Text] [Related]
13. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. J Natl Cancer Inst; 1997 Dec 03; 89(23):1789-96. PubMed ID: 9392620 [Abstract] [Full Text] [Related]
14. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro. Shrieve DC, Denekamp J, Minchinton AI. Radiat Res; 1985 Jun 03; 102(3):283-94. PubMed ID: 4070545 [Abstract] [Full Text] [Related]
15. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow. Ono K, Shrieve DC. J Natl Cancer Inst; 1987 Oct 03; 79(4):811-5. PubMed ID: 3477662 [Abstract] [Full Text] [Related]
16. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K. Oncol Res; 1995 Oct 03; 7(3-4):191-200. PubMed ID: 8555653 [Abstract] [Full Text] [Related]
17. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Siemann DW, Beyers KL. Br J Cancer; 1993 Dec 03; 68(6):1071-9. PubMed ID: 8260357 [Abstract] [Full Text] [Related]
18. Evidence for embryonic peroxidase-catalyzed bioactivation and glutathione-dependent cytoprotection in phenytoin teratogenicity: modulation by eicosatetraynoic acid and buthionine sulfoximine in murine embryo culture. Miranda AF, Wiley MJ, Wells PG. Toxicol Appl Pharmacol; 1994 Feb 03; 124(2):230-41. PubMed ID: 8122268 [Abstract] [Full Text] [Related]
19. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance. Xu BH, Gupta V, Singh SV. Arch Biochem Biophys; 1994 Jan 03; 308(1):164-70. PubMed ID: 8311448 [Abstract] [Full Text] [Related]